Advances in BTK Inhibitor Therapy for B-Cell Lymphomas: Expert Discussion and Resources to Elevate Patient Care

In this on-demand webcast, an expert discusses the latest developments in the use of BTK inhibitors as a targeted therapy for B-cell lymphomas. Tune in for a discussion about the mechanisms of action, emerging treatment regimens, and patient management strategies to enhance outcomes.

• Explain differences in BTK inhibitors to patients with B-cell lymphomas, including current and emerging indications, safety, and treatment resistance

• Develop strategies to maintain adherence and persistence to prescribed BTK inhibitor regimens for patients with B-cell lymphomas

• Manage and mitigate adverse events associated with BTK inhibitor therapy in patients with B-cell lymphomas

• Counsel patients with B-cell malignancies on ongoing clinical trial opportunities with BTK inhibitor therapy to ensure inclusive enrollment opportunities and equitable care

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until June 10, 2025. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author